

HISTORICALLY ACCEPTED USE

Tertiary and Quaternary Committee

Executive Summary

Date: June 2019
Medicine (INN): Cisplatin
Medicine (ATC): L01XA01
Indication (ICD10 code): Adjuvant/Neoadjuvant: various cancers.
Patient population: children and adults
Prevalence of condition: Various cancers
Level of Care: Tertiary and Quaternary
Prescriber Level: Oncologist and haematologist (adult and paediatric)
Current standard of Care: Cisplatin alone or in combination
Efficacy estimates: Established standard of care

Historically accepted use Criteria

Criteria		Comment	
1	The medicine is included in the WHO Model Essential Medicines List, either as a core or complementary item, for the indication requested.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
2	The medicine is currently registered by SAHPRA for the indication.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
3	There is evidence of long-established (prior to 1996*) safe and effective use of the medicine for the recognised indication in the public health sector.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
4	There are no new safety or efficacy concerns.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
5	The budget impact is not expected to be sufficiently large that a de novo review is justified.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
6	There is equitable access across the country, and is limited only by the availability of adequately trained staff and availability of equipment.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	

* The Essential Drugs Programme (EDP) of South Africa was established in terms of the National Drug Policy (NDP) which was implemented in 1996

Recommendation

It is recommended that cisplatin be included as an Essential Medicine for the adjuvant/neoadjuvant management of various cancers